"Nolpaz": instructions for the use of tablets in case of gastric and duodenal ulcer

"Nolpaz" is a hypoacid drug related to antiulcer drugs, to a group that inhibits the proton pump. The drug is used to prevent and treat pathologies of the digestive tract. There are analogues for the Nolpaz drug, such as Panum, Zepantola, Controller, Pepazol, Sunpras, and Pantaz. All of them have in their composition the active substance "pantoprazole", which dose-dependent and long-term effects on the suppression of the secretion of hydrochloric acid.

Composition and form of the preparation "Nolpaz"

The instruction informs, that in 1 tablet of gastroresistant medication "Nolpaz 20" contains 20 mg of pantaprazole. In the tablet "Nolpaz 40" - 40 mg of the active substance. Also, there are auxiliary substances in the preparation, including sorbitol.

Pharmacological action of the drug "Nolpaz"

The instruction refers the drug to antiulcer drugs - inhibitors of the proton pump (H + K + ATPase). The drug has the ability to prolong the suppression of the secretion of hydrochloric acid. The drug is active against Helicobacter pylori and is able to enhance the anti-Helicobacter effect of other drugs.

After taking the Nolpaz tablet, the therapeutic effect manifests itself fairly soon and continues throughout the day. With an intravenous injection of 80 mg of the drug, antisecretory action reaches a peak within an hour and persists for 24 hours, which contributes to the rapid reduction of symptoms and the healing of ulcers in the duodenum. When ingested, complete absorption occurs quickly. To a small extent, the medicine has the ability to penetrate the BBB, along with the secret is found in breast milk. Metabolism of the drug occurs in the liver. In the form of metabolites is excreted, mainly in the urine, in small amounts can be found in the stool. Has no cumulative ability.

Indications for the drug "Nolpaz"

The instruction provides for the use of the drug when:

- gastroesophageal reflux pathology of mild degree;

- for prevention and treatment of patients with reflux esophagitis at any stage;

- for therapy of people with gastric or intestinal peptic ulcer, with Zollinger-Ellison syndrome and other conditions accompanied by hypersecretion;

- to prevent ulcers in patients who have been receiving nonsteroidal anti-inflammatory drugs for a long time .

The drug "Nolpaz" can be prescribed in a complex therapy with antimicrobial drugs for the destruction of Helicobacter pylori.

Contraindications to the drug "Nolpaz"

The instruction does not recommend the use of the drug for hypersensitivity, hepatitis and cirrhosis of the liver, accompanied by severe hepatic insufficiency .

Restrictions on the use of the drug "Nolpaz"

- with violations of the liver,

- in childhood,

- during pregnancy, lactation.

Side effects

In the organs of the gastrointestinal tract are manifested:

- diarrhea;

- dry mouth,

- increased appetite,

- nausea,

- belching,

- vomiting,

- Flatulence,

- pain in the abdomen,

- constipation,

- increased activity of transaminases,

- Gastrointestinal carcinoma.

In the nervous system and sensory organs:

- headache;

- asthenia, dizziness, drowsiness, insomnia;

- nervousness, depression, tremor, paresthesia;

- photophobia, visual impairment, noise in the ears.

In the genitourinary system:

- hematuria,

- edema,

- impotence.

On the skin:

- alopecia,

- Acne,

- exfoliative dermatitis,

- Allergic reactions in the form of rash, hives, itching, angioedema.

Other in the form:

- Hyperglycemia, myalgia;

- fever, eosinophilia, hyperlipoproteinemia, hypercholesterolemia.

Interaction with other drugs

With the simultaneous use of the drug "Nolpaz" with other medications, the assimilation of ketoconazole and some other drugs with pH-dependent absorption is reduced.

Methods of application

Tablets "Nolpaz" are taken orally, 40 mg - 1 reception per day, in the morning. The maximum dose of the medicine is two times that.

In the treatment of ulcerative lesions caused by Helicobacter pylori, therapy schemes are used in conjunction with clarithromycin and metronidazole.

Overdose

There are no descriptions of symptoms. In case of an overdose, it is recommended to carry out maintenance and symptomatic therapy. Dialysis in this case is considered ineffective.

special instructions

Before treatment, it is necessary to exclude the presence of malignant diseases of the esophagus and stomach. It is not recommended to appoint patients with dyspepsia of nonulcer etiology. Elderly patients and with impaired renal function is not recommended to give a dose exceeding 40 mg / day. If there is severe hepatic insufficiency, the dosage regimen should be adjusted, controlling the level of hepatic enzymes.